© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Expert gynecologic oncologist Brian Slomovitz, MD, MS, FACOG, shares insight on novel therapeutic approaches to the management of endometrial cancer.
January 14th 2022
Expert perspectives on the endometrial cancer treatment landscape in light of approved therapies and drug classes.
Brian Slomovitz, MD, MS, FACOG, provides a brief review of endometrial cancer relapse and corresponding therapeutic approaches.
Insight on the combination of lenvatinib and pembrolizumab in endometrial cancer, investigated between the KEYNOTE-146 and KEYNOTE-775 trials.
Practical perspectives on the optimal use of combination lenvatinib-pembrolizumab in endometrial cancer.
Brian Slomovitz, MD, MS, FACOG, shares excitement for novel and combination therapies being investigated in the endometrial cancer landscape.
Reflections on the future management of endometrial cancer and practical advice for practicing oncologists.